Biologic
RCSB PDB 9SFX
Secukinumab
Cosentyx
- Mechanism of action
- IL-17A antagonist (mAb)
- In plain language
- A lab-made antibody that neutralizes IL-17A, an inflammation-driving protein linked to psoriasis and related conditions.
- How it works
- Secukinumab is a fully human IgG1 monoclonal antibody that selectively binds interleukin-17A and prevents it from engaging the IL-17 receptor on target cells. By neutralizing this cytokine, it interrupts a key signaling pathway that drives release of proinflammatory mediators implicated in psoriatic and spondyloarthritic disease, reducing keratinocyte hyperproliferation in skin and inflammatory infiltration in joints and entheses.
- Therapeutic applications
- FDA-indicated for moderate to severe plaque psoriasis, active psoriatic arthritis, active ankylosing spondylitis, active non-radiographic axial spondyloarthritis, active enthesitis-related arthritis, and moderate to severe hidradenitis suppurativa, across various age ranges from adults to children as young as 2.
- Class
- Monoclonal antibody
- Therapeutic area
- Immunology
View
Related compounds